Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotyping Hepatic Immune-Related Adverse Events in the Setting of Immune Checkpoint Inhibitor Therapy.

JCO clinical cancer informatics - 1 May 2024

Feldman Theodore C, Kaplan David E, Lin Albert, La Jennifer, Lee Jerry S H, Aljehani Mayada, Tuck David P, Brophy Mary T, Fillmore Nathanael R, Do Nhan V

Abstract excerpt

PURPOSE: We present and validate a rule-based algorithm for the detection of moderate to severe liver-related immune-related adverse events (irAEs) in a real-world patient cohort. The algorithm can be applied to studies of irAEs in large data sets. METHODS: We developed a set of criteria to define hepatic irAEs. The criteria include: the temporality of elevated laboratory measurements in the first 2-14 weeks of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Algorithms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Hepatocellular

Share to Chemical and Drug Induced Liver Injury

Share to Drug-Related Side Effects and Adverse Reactions

Share to Immune Checkpoint Inhibitors

Share to Liver Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38728613
DOI: 10.1200/CCI.23.00159
PMCID: PMC11161238

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotyping Hepatic Immune-Related Adverse Events in the Setting of Immune Checkpoint Inhibitor Therapy.PMID 38728613Read ↗

Hepatic Failure Associated with Immune Checkpoint Inhibitors: A Real-world Study from the Food and Drug Administration Adverse Event Reporting System (FAERS) DatabaseSemantic proximity Read ↗

Construction and evaluation of clinical prediction model for immunotherapy-related adverse events and clinical benefit in cancer patients receiving immune checkpoint inhibitors based on serum cytokine levelsSemantic proximity Read ↗

Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors.Semantic proximity Read ↗

Association of Blood Biomarkers and Autoimmunity with Immune Related Adverse Events in Patients with Cancer treated with Immune Checkpoint InhibitorsSemantic proximity Read ↗

Drug-induced liver injury: a safety review.Semantic proximity Read ↗

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune liver diseaseSemantic proximity Read ↗

Baseline risk factors associated with immune related adverse events and atezolizumabSemantic proximity Read ↗

Application of Tocilizumab in Drug-Induced Liver Injury: Pharmacovigilance Study Using the FAERS Database and the Drug-Gene Interaction Network AnalysisSemantic proximity Read ↗

Development of a Digital Phenotype for Immune-Related Colitis.Semantic proximity Read ↗

A Clinically Grounded Rule-Based Phenotyping Framework for Identifying Immune-Related Adverse Events in Structured Electronic Health Record Data: A Retrospective EHR StudySemantic proximity Read ↗

Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in SwedenSemantic proximity Read ↗

A collaborative approach to developing an electronic health record phenotyping algorithm for drug-induced liver injury.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.